The global genome editing market size is expected to reach USD 30.23 Billion in 2030 and register a revenue CAGR of 18.2% during the forecast period. Rising prevalence of genetic abnormalities, cancer, and infectious disease, growing application of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome in different fields of biotechnology increasing funding for research initiatives in the field, and rising demand for gene-editing technologies in pharmaceutical companies are some of the major factors driving global genome editing market revenue growth.
Genome editing, also known as gene editing or genome engineering, is a process used to change or modify gene sequence of an organism. This process allows scientists to add, alter, or remove genetic material at specific locations in the genome. Genome editing is applied in different domains such as pharmaceutical research, academic research, applied biotechnology, and biomedical research.
Different types of technologies such as CRISPR, Zinc-finger Nucleases (ZFNs), Transcription Activator-like Effector Nucleases (TALEN), antisense, and others are used to perform genome editing. CRISPR is a novel gene-editing technology consisting of two major components, namely, Cas9, which is an enzyme, and gRNA or guide RNA, which are used to start the mutation process. Cas9 functions as a pair of molecular scissors that can divide two strands of DNA at any particular place in the genome so that bits of DNA can be attached or removed. Guide RNA helps Cas9 to reach the targeted part of the genome.
Request a Sample@ https://qyresearchmedical.com/sample/119069
Rapid advancements in gene-editing technologies, increasing investment by governments and private entities in biotechnology and biomedical research, and increasing application of gene-editing technology in fields such as gene therapy, therapeutics, mutations, agricultural biotechnology, and others are some other key factors expected to continue to drive revenue growth of the global genome editing market to a significant extent over the forecast period.
Driver: Increased government funding and number of genomics projects
Governments in various countries across the globe are investing significantly in genomics, which has aided in the development of more novel genome editing technologies. Furthermore, government funding has enabled academic and government institutes to conduct extensive genome editing research. On 2 March 2022 for example, The Minister of Innovation, Science, and Industry announced USD 13.8 million in federal support through Genome Canada to 10 downstream research and development projects that will mobilize genomics out of the lab and deliver real-world benefits. These are projects are aimed to harness the game-changing power and potential of genomics to deliver solutions to build healthier, more sustainable and prosperous communities across Canada.
In March 2020, Parliamentary Secretary to Minister of Innovation, Science and Industry (Science), announced USD 14.7 million awarded through Genome Canada to support 11 genomics research projects. In addition, provincial governments, businesses, and research partners invest USD 29.7 million for a total of USD 44.4 million in support of these projects in the areas of health, agriculture, and the environment. The projects involve cervical and ovarian cancer research. The number of genomics research projects has increased significantly as a result of significant government investments in genomics. This, in turn, is likely to continue to drive global genome editing market revenue growth over the forecast period.
Restraint: High cost of equipment
Genomic research requires advanced instruments or tools. Genomic instruments include advanced functionalities and features, they are more expensive, ranging from USD 10–20 million. Pharmaceutical companies and research laboratories spend significantly on various vital genomics equipment. Small and medium-sized pharmaceutical companies and research laboratories are limited by budget constraints and lack certain high-cost genomics equipment. Similarly, budget constraints limit academic research laboratories from purchasing such equipment. Moreover, lack of skilled researchers and negative impacts of off-target editing are other factors expected to hamper genome editing market revenue growth to some extent over the forecast period.
Some Key Takeaways:
Based on technology, the global genome editing market has been segmented into Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Zinc-finger Nucleases (ZFNs), Transcription Activator-like Effector Nucleases (TALEN), Antisense, and others. CRISPR segment is expected to register fastest revenue CAGR over the forecast period. This can be attributed to increasing preference for CRISPR in the gene alteration process due to various advantages such as cost-effectiveness, enhanced efficacy, and ease of use. CRISPR systems are based on self-/nonself-discrimination principle to mediate immunity against invading pathogens and mobile genetic elements. Most archaea and many bacteria have these systems encoded in their genomes, and these work as real adaptive immunity mechanisms that target specific sequences in plasmid or viral genomes. The CRISPR/Cas9 system has the potential to easily and efficiently modify genes in a wide range of cell types, including malignant or pre-malignant cell types, which have previously been difficult to genetically manipulate. This technology also enables researchers to gain a better understanding of the genome’s functional organization and to establish links between genetic variation and phenotype.
Zinc-finger Nucleases segment revenue is expected to increase significantly during the forecast period. ZFNs are DNA cleavage reagents that have been used to target certain genes. ZFN-induced double-strand breaks are subjected to cellular DNA repair processes, which result in high frequencies of targeted mutagenesis and gene replacement. Many plants and animals have genomes that can be manipulated using zinc-finger nucleases. ZFNs are also used to create new generation of genetic disease models called isogenic human disease models. Zinc finger nucleases have been used in a clinical trial of CD4+ human T-cells with the CCR5 gene disrupted by zinc-finger nucleases to be saved as a potential HIV/AIDS treatment. Zinc-finger nucleases have been utilized to eradicate latent infections while also providing resistance to new infections. A genome editing-based antiviral method is very simple to develop and can be easily adapted to combat infections caused by a broad spectrum of viral pathogens, including coronaviruses.
Product & Service Outlook:
Based on product & service, the global genome editing market has been segmented into software & systems, reagents & consumables, and services. Reagents & consumables segment is expected to register a significantly rapid revenue CAGR over the forecast period. This can be attributed to repeated purchases of reagents and consumables, as well as expanding application areas of editing and sequencing. Increasing applications of genomics in various fields is a key factor expected to continue to drive revenue growth of this segment.
Based on application, the global genome editing market has been segmented into cell line engineering, diagnostic applications, genetic engineering, drug discovery & development, and others. Drug discovery & development segment revenue is expected to register a significantly robust growth rate over the forecast period. The ability to manipulate genomes is critical during the preclinical stage of drug discovery. Scientists can create an array of assays to identify disease targets and test therapeutic efficacy by modifying the sequence or expression of genes. CRISPR has improved cell-based screens by enabling scientists to generate cell lines with mutations that are related to the disease of interest with more precision. Multiple mutations can be produced simultaneously with CRISPR; for example, to better match disease genotypes. These initial screens can accurately eliminate ineffective compounds and find the most efficacious ones early in the drug discovery process with superior cellular models, saving time and cost.
Cell line engineering is utilized to manipulate stem cells in stem cell research, resulting in the rapid multiplication of pluripotent stem cell (iPSC) lines. The cell-line engineering method is also utilized in genetic engineering to create new antibodies for a variety of therapeutic uses, and especially ideal for mammalian cell engineering. Benefits of cell line engineering have not been limited to antibody production and have been investigated in the production of other bio pharmaceutical products such as vaccines, recombinant proteins, fusion proteins, growth factors, and others.
Based on end-use, the global genome editing market has been segmented into pharmaceutical companies, biotechnology companies, and academic & government research institutes. Pharmaceuticals companies segment accounted for largest revenue share in the global genome editing market in 2021. Increasing number of research activities for novel therapeutic development are major factors contributing to revenue growth of this segment. Prevalence of cancer and infectious diseases is rising, which is driving an increase in number of research activities globally and resulting in rising demand for genome editing in pharmaceuticals companies. Several genome editing approaches have been developed by pharmaceutical companies, with a majority relying on nucleases to alter the genomes in a targeted manner. Such developments and achievements are expected to further drive research activities and initiatives, and support revenue growth of this segment.
Academic & government research institutes segment revenue is expected to expand rapidly over the forecast period, owing to growing use of gene-editing technologies in university-level projects. For example, Rice University, Baylor College of Medicine, and the Whitehead Institute are all actively engaged in activities to advance genome editing. Increasing research activities is expected to drive demand for gene-editing technologies and support revenue growth of this segment.
Based on regional analysis, the market in North America accounted for largest revenue share in 2021 and is expected to register fastest revenue CAGR over the forecast period. Increased use of genetically modified crops, increasing frequency of outbreaks of infectious diseases and prevalence of cancer, and provision of research grants and funding are some key factors driving market revenue growth in the region. Moreover, presence of strong research as well as commercial bases for advanced therapeutic developments in countries in the region and large number of clinical trials for gene and stem cell therapies are other factors expected to drive revenue growth of the North America market.
Genome editing market in Asia Pacific is expected to account for a comparatively larger revenue share than other regional markets over the forecast period. This can be attributed to growing emphasis on drug discovery and development activities and surging prevalence of infectious diseases. Also, increasing government support and investments in research, and expanding number of applications of gene synthesis for genetic engineering of cells and tissues of organisms are key major factors supporting revenue growth of the genome editing market in Asia Pacific.
Market in Europe is expected to register a steady revenue CAGR over the forecast period. Increasing investment and funding by private organizations and governments, technological advancements, and increasing genomic projects are key factors supporting market revenue growth in the region. Moreover, scope for consumer genomics to aid in promoting awareness of genetic diseases, and generate personalized data about health, disease risk, and other traits is expected to have a positive impact on the market in the region.
Competitive landscape of the global genome editing market is moderately fragmented with a number of key players operating on global and regional levels. Major players are engaged in product development and strategic alliances to expand their respective product portfolios and gain a robust footprint in the global market. Some major companies in the market report include GenScript, Sangamo Therapeutics, Editas Medicine, CRISPR Therapeutics, Precision Biosciences, Agilent Technologies, Inc., Intellia Therapeutics, Inc., Bluebird Bio, Inc., Regeneron Pharmaceuticals, and Creative Biogene.
Some recent developments:
- On 18 April 2022, it was announced that Thermo Fisher Scientific has introduced the new GMP-manufactured Gibco CTS TrueCut Cas9 Protein. TrueCut Cas9 proteins are manufactured to comply with United States Pharmacopeia standards, including traceability documentation, aseptic manufacturing and safety testing. The addition of Gibco CTS TrueCut Cas9 Protein to Thermo Fisher Scientific’s portfolio of genome editing solutions is to support scientists in their journey to develop personalized CAR T-cell therapeutics.
- On 2 September 2021, KromaTiD launched a new product called dGH Screen for mapping the human genome in single cells. The tool uses the company’s proprietary directional genomic hybridization (dGH) technology, which is a platform for measuring genomic structure and structural variation.
- On 7 May 2020, Caribou Science entered into a commercial and clinical license agreement with MaxCyte. The agreement was aimed at gaining exclusive rights to use MaxCyte’s flow electroporation technology as well as ExPERT platform. This is slated to advance Caribou’s gene-edited allogeneic T cell therapy programs and expand the company’s corporate relations in the market.
- On 12 June 2019, Allele Biotechnology and Alpine BioTherapeutics Corporation announced an agreement for developing induced pluripotent stem cells for the treatment of retinal diseases. This strategy assisted the company in developing an advanced product portfolio.
Segments Covered in the report
This report offers historical data and forecasts revenue growth at a global, regional, and country-level, and provides analysis of the market trends in each of the segments, sub-segments, regions, and countries from 2022 to 2030. For the purpose of this report, Reports and Data has segmented the global genome editing market based on technology, product & service, application, end-use, and region:
Genome Editing Market Report Scope
Segments covered By Technology Outlook, Product & Service Outlook, Application Outlook, End-Use Outlook, Regional Outlook
By Technology Outlook
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
Zinc-finger Nucleases (ZFNs)
Transcription Activator-like Effector Nucleases (TALEN)
By Product & Service Outlook
Software & Systems
Reagents & Consumables
By Application Outlook
Cell Line Engineering
Drug Discovery & Development
By End-Use Outlook
Academic & Government Research Institutes
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119069/1500
You can place an order or ask any questions, please feel free to contact [email protected] | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/